TD Cowen analyst Daniel Brennan maintained a Buy rating on NeoGenomics today and set a price target of $14.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Daniel Brennan has given his Buy rating due to a combination of factors that suggest strong future growth for NeoGenomics. The company has demonstrated a solid performance with a 2% top-line and approximately 70 basis points EBITDA beat compared to consensus, alongside an 11% revenue growth on a CAGR basis. This sets a strong foundation for the anticipated launches of MRD and PanTracer liquid products in the first quarter of 2026, which are expected to accelerate growth.
Additionally, NeoGenomics is poised to benefit from its renewed focus on turnaround time and an expanded sales force, which have already shown positive results in its core non-NGS business. Despite challenges in the Pharma sector, the clinical business is projected to drive over 10% growth into 2026, supported by new test additions and improved market share retention. The company’s strategic initiatives and expected product launches have led to an increased price target of $14, reflecting confidence in its growth trajectory.
In another report released today, Needham also reiterated a Buy rating on the stock with a $14.00 price target.
Based on the recent corporate insider activity of 36 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of NEO in relation to earlier this year.